178. Dr. Matt Kaeberlein: The Science, Risk, and Hype Behind Today's Longevity Trends episode artwork

EPISODE · Jul 2, 2026 · 1H 14M

178. Dr. Matt Kaeberlein: The Science, Risk, and Hype Behind Today's Longevity Trends

from Extend Podcast with Darshan Shah, MD

If you care about longevity, you have probably seen the same pattern over and over again. A new peptide, supplement, biological age test, off-label drug, or protocol starts gaining attention, and suddenly it sounds like the missing piece everyone should be using. The hard part is not wanting to be proactive. The hard part is knowing which claims have real evidence behind them, which ones are still early signals, and which ones may carry risks no one is measuring carefully enough. In this episode, I sit down with Dr. Matt Kaeberlein to talk about how to think about longevity when the answer is rarely a simple yes or no. This conversation helps separate excitement from certainty, and shows why the real question is not only whether something might work, but whether the evidence, safety data, product quality, and risk-reward equation are strong enough to act on. Dr. Matt Kaeberlein is a scientist in the biology of aging and one of the most respected voices bringing scientific discipline to the longevity conversation. He has been involved with the Interventions Testing Program, which rigorously tests aging interventions in mice, and is one of the leaders behind the Dog Aging Project, a large-scale study looking at aging, health, and longevity in companion dogs. His work sits at the intersection of curiosity and caution, which makes him the right person to talk about what is promising, what is overhyped, and what still needs better evidence. What's Discussed: (03:24) Why longevity marketing can move faster than the science. (06:31) The risk-reward question most people skip before trying a new therapy. (09:39) Why years of peptide use does not automatically mean safety is proven. (20:00) The "research use only" peptide problem and why product quality matters. (34:51) How the Interventions Testing Program separates stronger longevity signals from noise. (38:39) Why rapamycin changed the field, and why some popular interventions failed to replicate. (58:43) What the Dog Aging Project may teach us about rapamycin, healthspan, and human aging. Listen to this episode of Extend to understand how to evaluate longevity claims with more clarity. You will hear what deserves excitement, what deserves caution, and what to ask before turning the next promising intervention into your personal health protocol. Thank You to Our Sponsors: Timeline: Timeline powered by Mitopure just dropped the price. Check it out at timeline.com/drshah and get an additional 20% off your first month with code DRSHAH.  IM8: Try IM8 today with a 30-day money back guarantee. You can get 10% off your first order with code DRSHAH at im8health.com/discount/DRSHAH.    Learn More About Dr. Darshan Shah: Website: drshah.com  Clinic: next-health.com  Instagram: darshanshahmd   Learn More About Dr. Matt Kaeberlein & the Dog Aging Project: Website: dogagingproject.org/  Instagram: @mkaeberlein  

Episode metadata supplied by the publisher feed · Published Jul 2, 2026

Embed this episode

Ready to play

178. Dr. Matt Kaeberlein: The Science, Risk, and Hype Behind Today's Longevity Trends

0:00 1:14:07

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Extend Podcast with Darshan Shah, MD?

This episode is 1 hour and 14 minutes long.

When was this Extend Podcast with Darshan Shah, MD episode published?

This episode was published on July 2, 2026.

Can I download this Extend Podcast with Darshan Shah, MD episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!